GlobeNewswire

Boyden Report Reveals C-Suite Rapidly Evolving CRM to Boost Growth

Dela

Led by CEOs and senior management, company-wide reorientation of CRM strategies and full compliance are imperative for effective implementation

FRANKFURT, Germany and LONDON, March 07, 2018 (GLOBE NEWSWIRE) -- CEO and senior management leadership are critical to the success of Customer Relationship Management (CRM) strategies, according to the Executive Monitor Report released today by Boyden.

The report explores the challenges and opportunities associated with the implementation of a CRM strategy, addressing the following issues:

  • CRM must be fully integrated into business processes at all corporate levels to ensure alignment and compliance
  • Increasingly enlisting CRM software and tools to achieve short and long-term objectives and engage more deeply with customers
  • Significant resources and human capital investment are necessary to appropriately elevate the initiative and encourage full engagement

Boyden's Executive Monitor reportThe C-Suite: Evolving Client Relationship Management, highlights the progress of CRM across industries and sectors, emphasizing the critical role of executive leadership and endorsement. Though the entire company must align around CRM and engage with the tools, executives, particularly the CEO, CDO, CMO and CIO, must elevate and spearhead the initiative.

The report is supported by in-depth interviews with Boyden partners and executives including Alex Sabbag, Former Chief Marketing Officer of Swiss department store chain MANOR and Desmond Edwards, Former Group Vice President of Digital Innovation of Bloomin' Brands.

"CRM is not the responsibility of one person or one function. It is a transversal responsibility that starts with the CEO and touches sales and marketing, technology, and the company at large," said Cornelia Tänzler, Managing Partner of Boyden Switzerland and Global Consumer & Retail Practice Leader.

"CRM interfaces now touch everyone every day. As these tools have expanded and become routine, CRM has transformed as a source of insight and knowledge for companies of all sizes, of all kinds, across the world," added Richard Fudickar, Managing Partner of Boyden Germany, who heads the firm's Automotive Practice.

The report also focuses on new opportunities and benefits to be gained from advancing CRM:

  • CRM synthesizes data from various sources to paint a more detailed and accurate picture of customer needs and preferences
  • Insights gleaned allow companies to tailor customer interactions, resulting in more efficient exchanges and elevated customer experiences
  • CRM provides direction for more effective management of revenues, expenses, and product inventories
  • With CRM tools, companies can ensure that promotions and campaigns reach and influence the appropriate target audience

"The C-suite plays a fundamental role in giving the appropriate weight to CRM across the business, thereby ensuring that it is executed appropriately across all layers of the business and all the way down to the customer," explained Anders Lindholm, Managing Partner of Boyden Italy and EMEA Leader of the firm's Social Impact Practice. "C-suite executives play a key role in putting CRM under the spotlight and encouraging total compliance with the strategy and the relevant measures and requirements."

"Implementing a successful CRM system is contingent upon the involvement and coordination of the entire business, with the insights feeding down throughout the entire supply chain," said Francesca d'Arcangeli, Managing Partner of Boyden United Kingdom.

About Boyden

Boyden is a premier leadership and talent advisory firm with more than 65 offices in over 40 countries. Our global reach enables us to serve client needs anywhere they conduct business. We connect great companies with great leaders through executive search, interim management and leadership consulting solutions. For further information, please visit www.boyden.com.

Contacts:

For Boyden Americas and EMEA:
Dan Margolis
T: +1 (213)452-6472
E. dan.margolis@fticonsulting.com
For Boyden Germany:
Jan Böhler
T: +49 (69) 13388041
E: j.boehler@wbco.de

Photos accompanying this announcement are available at

http://www.globenewswire.com/NewsRoom/AttachmentNg/a4956770-cad2-49d4-b7c2-93354b1990dc

http://www.globenewswire.com/NewsRoom/AttachmentNg/bc81eb86-c0e3-428e-9dd3-8cb7c085f63b




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Boyden via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum